Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026)

Janux Therapeutics (JANX) has 5 years of Non-Current Deffered Revenue data on file, last reported at $8.7 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (changed N/A YoY) and the FY2022 annual result came in at $2.2 million, up 217.29% from the prior year.
• Non-Current Deffered Revenue rose to $8.7 million in Q1 2026 per JANX's latest filing, from $307000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $8.7 million in Q1 2026 and bottomed at $307000.0 in Q2 2023.
• The 3-year median for Non-Current Deffered Revenue is $3.0 million (2022), against an average of $3.6 million.
• The widest annual swing landed in 2022, when Non-Current Deffered Revenue soared 217.29%; it then slumped 94.2% in 2023.
• Tracing JANX's Non-Current Deffered Revenue over 3 years: stood at $2.2 million in 2022, then tumbled by 86.18% to $307000.0 in 2023, then jumped by 2726.06% to $8.7 million in 2026.
• Per Business Quant, the three latest JANX Non-Current Deffered Revenue figures stand at $8.7 million (Q1 2026), $307000.0 (Q2 2023), and $1.4 million (Q1 2023).

Peer Comparison